Frequency of cardiovascular complications in patients with type 2 diabetes mellitus depending on antihyperglycemic therapy

Main Article Content

Z.G. Krushinska
T.Yu. Yuzvenko
V.I. Pankiv


Background. The purpose of the study was to determine the frequency of cardiovascular complications in patients with type 2 diabetes mellitus (DM) depending on the type of antihyperglycemic therapy. Materials and methods. Patients were divided into 3 groups: first group — all patients with type 2 DM included in the study (n = 1999), second group were patients (n = 201) with DM with myocardial infarction from the first group, third group were patients with DM with stroke from the first group (n = 155). Results. It was found that actually every second patient in the second group had angina pectoris — 48.3 % that is 2.7 times higher of the same index in the first group (18.2 %) and 1.7 times — in the third group (29.0 %). Every fifth patient in the second and third groups had heart rhythm disorder (in the first group — 11.2 %, in the second group — 20.9 %, in the third group — 20.7 %), its incidence was highest in men of this group (27.7 and 23.1 %, respectively). Arterial hypertension is the third common in the structure of concomitant cardiovascular pathology in patients with DM, more often in patients of the third group (in the first group — 74.6 %, in the second group — 76.6 %, in the third group — 80.7 %), most often in women in every group (78.7, 84.3 and 84.4 %, respectively). Coronary artery bypass surgery is conducted in 38 patients, the proportion among other operative interventions is highest in the second group (in the first group — 11.9 %, in the second group — 12.7 %, in the third group — 9.8 %). Conclusions. The proportion of patients who received monotherapy with insulin preparations is highest in the second group (17.4 %), actually at one level — in the first and third groups (12.8 and 12.3 %, respectively). The majority of patients in the first group received monotherapy with oral hypoglycemic agents (56.2 against 46.2 % in the second group and 49.7 % — in the third group), due to an increase in the proportion of patients with insulin monotherapy. Every third patient in the second and third groups (34.3 and 34.8 %, respectively) received combined therapy with insulins and oral hypoglycemic preparations.

Article Details

How to Cite
Krushinska, Z., T. Yuzvenko, and V. Pankiv. “Frequency of Cardiovascular Complications in Patients With Type 2 Diabetes Mellitus Depending on Antihyperglycemic Therapy”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 14, no. 6, Nov. 2018, pp. 570-8, doi:10.22141/2224-0721.14.6.2018.146067.
Original Researches


Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2014. Available from:

Beckman JA, Paneni F, Cosentino F, Creager MA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. Eur Heart J. 2013 Aug;34(31):2444-52. doi: 10.1093/eurheartj/eht142.

Khalimov YS, Salukhov VV. Cardiovascular safety of modern insulin analogues: is there a reason for optimism? Endokrinologia. Novosti, mnenia, obucenie. 2014;(8):24-29. (in Russian).

Introduction: Standards of Medical Care in Diabetes - 2018. Diabetes Care. 2018 Jan;41(Suppl 1):S1-S2. doi: 10.2337/dc18-Sint01.

Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018 Feb;14(2):88-98. doi: 10.1038/nrendo.2017.151.

Low Wang CC, Hess CN, Hiatt WR, Goldfine AB. Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus – mechanisms, management, and clinical considerations. Circulation. 2016 Jun 14;133(24):2459-502. doi: 10.1161/CIRCULATIONAHA.116.022194.

Sokolova LA, Ievskaia EV. Insulin resistance as risk factor of cardiovascular diseases. Translational medicine. 2015;(6):32-38. doi: 10.18705/2311-4495-2015-0-6-32-38. (in Russian).

Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2017 Mar 7;135(10):e146-e603. doi: 10.1161/CIR.0000000000000485.

Emerging Risk Factors Collaboration, Sarwar N, Gao P, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010 Jun 26;375(9733):2215-22. doi: 10.1016/S0140-6736(10)60484-9.

Shu L, Chan KHK, Zhang G, et al. Shared genetic regulatory networks for cardiovascular disease and type 2 diabetes in multiple populations of diverse ethnicities in the United States. PLoS Genet. 2017 Sep 28;13(9):e1007040. doi: 10.1371/journal.pgen.1007040.

Davies MJ, D'Alessio DA, Fradkin J, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018 Oct 4. pii: dci180033. doi: 10.2337/dci18-0033.

Jabbour SA, Frías JP, Hardy E, et al. Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial. Diabetes Care. 2018 Oct;41(10):2136-2146. doi: 10.2337/dc18-0680.

Wanner C, Marx N. SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases. Diabetologia. 2018 Oct;61(10):2134-2139. doi: 10.1007/s00125-018-4678-z.

Inzucchi SE, Zinman B, Fitchett D, et al. How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care. 2018 Feb;41(2):356-363. doi: 10.2337/dc17-1096.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 11 12 > >>